Recent Advances in Application of Pharmacogenomics for Biotherapeutics

Abstract

Abstract.Biotherapeutics (BTs), one of the fastest growing classes of drug molecules, offer several advantages over the traditional small molecule pharmaceuticals because of their relatively high specificity, low off-target effects, and biocompatible metabolism, in addition to legal and logistic advantages. However, their clinical utility is limited, among other things, by their high immunogenic potential and/or variable therapeutic efficacy in different patient populations. Both of these issues, also commonly experienced with small molecule drugs, have been addressed effectively in a number of cases by the successful application of pharmacogenomic tools and approaches. In this introductory article of the special issue, we review the current state of application of pharmacogenomics to BTs and offer suggestions for further expansion of the field.

Antibodyomics: bioinformatics technologies for understanding B‐cell immunity to HIV‐1

“…One of the fastest growing areas of biotherapeutics is the use of monoclonal antibodies, especially in the treatment of cancer, autoimmune disorders, and infectious diseases 92. One roadblock to achieving effective therapies is the long and costly process of antibody optimization, which may require years of effort.…”

“…One of the fastest growing areas of biotherapeutics is the use of monoclonal antibodies, especially in the treatment of cancer, autoimmune disorders, and infectious diseases. 92 One roadblock to achieving effective therapies is the long and costly process of antibody optimization, which may require years of effort. Computational approaches may aid in this process, but their effective implementation has been difficult because current tools fail to yield predictions of sufficient accuracy.…”